Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MRNA sequencing of single-cell and 20-cell pools of CD103+CD8+ and CD103-CD8+ T lymphocytes sorted from human ovarian cancer

ABSTRACT: mRNA sequencing of single-cell and 20-cell pools of CD103+CD8+ and CD103-CD8+ T lymphocytes sorted from human ovarian cancer

PROVIDER: PRJNA525699 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8671320.fastq.gz	Fastqsanger.gz
	SRR8671330.fastq.gz	Fastqsanger.gz
	SRR8671340.fastq.gz	Fastqsanger.gz
	SRR8671350.fastq.gz	Fastqsanger.gz
	SRR8671360.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 120

Similar Datasets

mRNA sequencing of single-cell and 20-cell pools of CD103+CD8+ and CD103-CD8+ T lymphocytes sorted from human ovarian cancer

Project description:Cytotoxic T cells confer a prognostic benefit in many tumors, including ovarian cancer. We and others have previously identified a subset of CD8+ T cells, namely CD103+CD8+ T cells, that seems to have a better prognostic effect. The aim of this study is to identify how these CD103+ T cells differ from CD103-CD8+ T cells on mRNA level in human samples of ovarian cancer.

2019-03-06 | GSE127888 | GEO

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

Project description:The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies. The TIL selection process is based on evidence showing that CD8+ TIL which co-express both CD39 and CD103 harbor the bulk of tumor-reactivity and that the remaining CD8 TIL is mainly composed of non-tumor reactive bystander cells. All of the expanded TIL that are produced (1-40 billion are expected) will be delivered in the form of a cell suspension to the participants by intravenous infusion. It is proposed that these selected TIL will produce a more potent and efficacious treatment of late-stage cancer.

| 63320 | ecrin-mdr-crc

FACS-sorted CD103+ and CD103- Treg cell proteomics

Project description:Regulatory T cells (Tregs) play a key role in suppressing systemic effector immune responses, thereby preventing autoimmune diseases but could also potentially contribute to tumor progression. As a result, there is significant interest in the clinical manipulation of Tregs. However, the mechanisms governing induced Treg (iTreg) differentiation are not fully understood. In the present study, we phenotypically profiled human iTregs during early stages of in vitro differentiation at single-cell level using multiparametric mass cytometry. A panel of 25 metal-conjugated antibodies specific to a range of markers associated with human Tregs was used to characterize these immunomodulatory cells. We found that iTregs highly express the transcription factor Foxp3 and characteristic Treg-associated surface markers (e.g. CD25, PD1, CD137, CCR4, CCR7, CXCR3, and CD103). Expression of co-inhibitory factors (e.g. TIM3, LAG3, and TIGIT) increased slightly at late stages of iTreg differentiation. Further, CD103 was selectively upregulated in the iTreg compartment while negatively regulated by Foxp3. Overall, our study highlights that during early stages of differentiation, iTregs resemble memory-like Treg features, and opens possibilities for studying molecular mechanisms of Treg function.

2025-05-07 | PXD052626 | Pride

RNA-seq transcriptome analysis of epidermal CD8+CD103+CD49a+ and CD8+CD103+CD49- T cells from healthy human skin

Project description:We report the transcriptome analysis of epidermal CD8 tissue resident memory T (TRM) cells from healthy human skin. Specifically, epidermal CD8+CD103+CD49a+ and CD8+CD103+CD49- TRM cells from healthy human skin were sorted by FACS. Differential gene expression analysis revealed functional dichotomy of epidermal CD8+CD103+CD49a+ and CD8+CD103+CD49- TRM cells.

2017-02-14 | GSE83637 | GEO

Transcriptome profile of naive CD8 T cells from WT and CD103 deficient mice

Project description:The Ly6C–CXCR3– naïve CD8 T cells highly express CD103. To understand the biological significance of CD103 expression on naïve CD8 T cells, we performed RNA sequencing on sorted naïve CD8 T cells from WT and CD103-dificient (Itgae–/–) mice to elucidate the function of CD103 expressed on naïve CD8 T cells.

2025-09-24 | GSE295528 | GEO

TGF-beta and IL-12 conversely orchestrate formation of CD103+ CD8 tumor-resident memory T cells to regulate response to therapeutic cancer vaccine [RNA-Seq]

Project description:Using mouse model, we show that CD8 tumor-infiltrating T lymphocytes (TIL) include two major resident T cells subpopulations expressing either CD49a or CD103 integrin, with a subset co-expressing CD103 and Tcf-1 transcription factor. Tumor vaccination induces a decrease in the percentage of Tcf-1+CD103+ TRM-like cells and an expansion of CD49a+ TRM displaying an effector/exhausted profile. Tcf-1+CD103+ TRM-cell density increases in tumors from vaccinated transgenic mice constitutively expressing active TGF-beta-type-2-receptor and wild-type mice challenged with neutralizing anti-IL-12 antibodies. Stimulation of mouse and human CD8 T cells with recombinant (r)TGF-beta combined with anti-CD3 antibodies results in increase in the proportion of CD103+ and Tcf-1+CD103+ CD8 T cells, whereas rIL-12 induces decrease in CD103 expression on CD8 T cells.

2025-05-27 | GSE298151 | GEO

An unconventional integrin b3 and CD103 heterodimer improves the anti-tumor immunity of tissue-resident T cells

Project description:Current cancer immunotherapies promote recovery of CD103+ tissue-resident memory T cells (Trm) population of the tumor-infiltrating T lymphocytes (TILs). However, not all treated patients exhibit improved anti-tumor immunity and survival, likely due to the immunophenotypical diversity among the CD103+ Trm TILs. Utilising multifaceted proteomics approaches and patients’ clinical analyses, we discovered an unusual subset of CD8+ Trm TILs expressing non-canonical integrin β3 early during T cells activation. The integrin β3 surprisingly heterodimerises with CD103 on T cells, leading to unconventional granulysin-mediated cytotoxicity, elevated alternative bioenergy usage and efficient T cell migration, with minimal overall exhaustion. Importantly, early-stage non-small cell lung carcinoma (NSCLC) patients with enriched presence of integrin β3+CD103+ Trm TILs exhibited better clinical prognosis, with improved T cell immunophenotype, hence confirming the beneficial role of this unusual subset of Trm TILs. These unconventional anti-tumor T cell features provide new avenues and future opportunities for designing better translational immunotherapy strategies.

2024-02-14 | PXD031794 | Pride

SKI-dependent TGFb signaling dictates CD103 expression in CD8+ T cells (ChIP-seq)

Project description:Initially identified as a functional marker for resident-memory (Trm) CD8+ T cells, CD103 (encoded by ITGAE gene) has broad roles in immunity and diseases. Elucidating the function and regulation of CD103 is thus of importance. This study revealed that the CD103 expression by CD8 T cells under steady state contributes to the clearance of acute viral infection. More importantly, it discovered TGF-SKI-Smad4 a critical signaling axis in restricting CD103 expression in CD8+ T cells for their function. Mechanistically, by ChIP-Seq and ChIP analysis, SKI associated with Smad4 was found to directly and epigenetically suppress CD103 transcription. This study therefore reveals a novel TGF-SKI-Smad4 pathway to specifically enable CD103 expression in CD8+ T cells for protective immunity.

2020-07-28 | GSE135533 | GEO

Retinoic acid signaling during priming licenses intestinal CD103+ CD8 TRM cell differentiation

Project description:CD8 tissue-resident memory T (TRM) cells provide front-line protection at barrier tissues; however, mechanisms regulating TRM cell development are not completely understood. Priming dictates the migration of effector T cells to the tissue, while factors in the tissue induce in situ TRM cell differentiation. Whether priming also regulates in situ TRM cell differentiation uncoupled from migration is unclear. Here, we demonstrate that T cell priming in the mesenteric lymph nodes (MLN) regulates CD103+ TRM cell differentiation in the intestine. In contrast, T cells primed in the spleen were impaired in the ability to differentiate into CD103+ TRM cells after entry into the intestine. MLN priming initiated a CD103+ TRM cell gene signature and licensed rapid CD103+ TRM cell differentiation in response to factors in the intestine. Licensing was regulated by retinoic acid signaling and primarily driven by factors other than CCR9 expression and CCR9-mediated gut homing. Thus, the MLN is specialized to promote intestinal CD103+ CD8 TRM cell development by licensing in situ differentiation.

2023-02-13 | GSE223983 | GEO

Transcriptome profile of memory phenotype CD8 T cells are shaped by overexpression of CD103

Project description:The CD8 T cells in the peripheral tissues maintained as a mixture of naïve and memory-phenotype in the steady state, while the mechanism how the balance of naïve and memory-phenotype CD8 T cells is controlled remains unclear. Here, we report that integrin CD103 plays critical role in this process. CD103 is differentially expressed on peripheral CD8 T cells with highest expression on naïve CD8 T cells (Ly6C–CXCR3–) and lowest expression on memory-phenotype CD8 T cells (Ly6C+CXCR3+). To understand the biological significance of CD103 downregulation on memory-phenotype CD8 T cells, we generated transgenic mice that overexpress CD103 under the control of the human CD2 promoter/enhancer so that CD103 is constitutively expressed on all T lineage cells (CD103Tg), and we found that memory-phenotype CD8 T cells are accumulated in CD103Tg mice. Therefore, we performed RNA sequencing on sorted memory-phenotype CD8 T cells from WT and CD103Tg mice to elucidate the molecular mechanism how forced expression of CD103 promotes accumulation of memory-phenotype CD8 T cells.

2025-09-24 | GSE295529 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data